Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovo Nordisk CEO on earnings: Very bullish on 2025 despite demand concernsLars Fruergaard Jørgensen, Novo Nordisk CEO, joins 'Money Movers' to discuss Jorgensen's comments on demand in 2025, if demand is waning for GLP-1 drugs, and much more.
Persons:
Lars Fruergaard Jørgensen
Organizations:
Novo Nordisk